Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

phenytoin sodium

- PMLiVE

Incyte Biosciences UK announces NICE approval for Opzelura for vitiligo

This is the first approved treatment option in the UK for patients with non-segmental vitiligo

Genetic Digital at the EHP Awards

EpilepsyMeds receives Highly Commended recognition at Excellence in Healthcare Partnership Awards 2026

EpilepsyMeds received Highly Commended recognition at the Excellence in Healthcare Partnership Awards 2026, celebrating the collaboration between Desitin Pharma, ChangeMed and Genetic Digital in advancing epilepsy care.

Genetic Digital

- PMLiVE

Pfizer’s Braftovi combination therapy shows positive results for colorectal cancer

Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022

- PMLiVE

Pfizer’s Hympavzi significantly reduces bleeds in haemophilia patients

Over 800,000 people worldwide live with haemophilia

- PMLiVE

UK and US agree on landmark pharma pricing tariff deal

US tariffs on UK-produced pharmaceuticals will remain at zero for three years

- PMLiVE

Pfizer’s PADCEV gets FDA approval for bladder cancer

Bladder cancer affects more than 614,000 people globally each year

- PMLiVE

Pfizer and Metsera agree on merger after bidding war between Pfizer and Novo Nordisk

The Pfizer bid was chosen by Metsera after a concern was raised about US antitrust laws regarding the Novo Nordisk offer

- PMLiVE

Novo Nordisk agrees to lower certain drug prices in the US

The company's semaglutide-based weight-loss drugs will be made available in the US through Medicare and Medicaid

- PMLiVE

Lilly announces agreement with US government to lower patient costs

The agreement will make insulin and obesity treatments more affordable through federal programmes and direct-to-patient channels

- PMLiVE

UCB’s Fintepla shows positives results for Lennox-Gastaut syndrome

The study demonstrated a sustained reduction in seizures for patients

- PMLiVE

ViiV Healthcare receives NICE recommendation for HIV prevention therapy

The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales

- PMLiVE

Pfizer’s Lorviqua recommended by NICE for lung cancer

Lung cancer is the leading cause of cancer-related deaths worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links